

Diagnosis & staging

36,886 patients were diagnosed with

lung cancer in 2022



of patients with stage I/II disease, performance status (PS) 0-1 had pathological confirmation of their diagnosis 83% in 2021, 77% in 2020 & 84% in 2019

34,235 in 2021, **31,371** in 2020 33.091 in 2019

(median)

age at diagnosis



of patients presented with stage IV disease 48% in 2021, 50% in 2020 & 47% in 2019



of patients were diagnosed via emergency presentation

35% in 2021, 35% in 2020 & 31% in 2019

Kev

93%



improving from 2021

worsening from 2021

unchanged from 2021



of patients* were assessed at

diagnosis by a lung cancer clinical nurse specialist: 92% in 2021, 75% in 2020 and 80% in 2019



≥90% Audit standard*

*information available for 60% of patients so this is uncertain

Treatment allocation

Surgery for non-small cell lung cancer (NSCLC)



of patients with NSCLC had surgical treatment for their cancer



Audit standard

17% in 2021 15% in 2020

20% in 2019

Chemotherapy for small cell lung cancer (SCLC)



of patients with SCLC received treatment with chemotherapy



Audit standard **72%** in 2021

≥70%

66% in 2020

69% in 2019

Treatment with curative intent



of patients with NSCLC (stage I/II, PS 0-2) received treatment with curative intent**



**surgery or radical radiotherapy



80% in 2021 **73%** in 2020

81% in 2019



of patients with NSCLC (stage IIIA, PS 0-2) received treatment with curative intent***



61% in 2021

51% in 2020

57% in 2019

***surgery, radical radiotherapy or multimodal combination with chemotherapy

Systemic anti-cancer therapy



of patients with NSCLC (stage I/II, PS 0-2) received treatment with curative intent**





63% in 2021 **55%** in 2020

Survival outcomes

17,564 patients were diagnosed between 1 January and 30 June 2022. For these patients:

Median survival



280 days in 2021 **306** days in 2020 **44%** in 2021 **44%** in 2020

One year survival

41% in 2019 **316** days in 2019 **54%** in 2019

Data quality

Completeness of key routine data items

Stage

Performance status

Morphology

Basis of diagnosis

CNS at diagnosis

Smoking status

89%





















86% in 2021

83% in 2021

65% in 2021

90% in 2021

59% in 2021

49% in 2021



Diagnosis & staging

diagnosed with lung cancer in 2022

2,244 in 2021, 2,067 in 2020 2,240 in 2019

age at diagnosis (median)



of patients with stage I/II disease, performance status (PS) 0-1 had pathological confirmation of their diagnosis **85%** in 2021, **83%** in 2020 & **86%** in 2019



of patients presented with stage IV disease 50% in 2021, 49% in 2020 & 48% in 2019



of patients were diagnosed via emergency presentation

24% in 2021, 28% in 2020 & 29% in 2019

Kev



improving from 2021

worsening from 2021

unchanged from 2021



of patients* were assessed at diagnosis by a lung cancer clinical nurse specialist:

94% in 2021, 93% in 2020 and 95% in 2019



≥90% Audit standard*

Treatment allocation

Surgery for non-small cell lung cancer (NSCLC)



of patients with NSCLC had surgical treatment for their cancer



≥17% Audit standard

13% in 2021 **11%** in 2020

15% in 2019

Chemotherapy for small cell lung cancer (SCLC)



of patients with SCLC received treatment with chemotherapy



≥70% Audit standard

71% in 2021 **58%** in 2020

65% in 2019

Treatment with curative intent



of patients with NSCLC (stage I/II, PS 0-2) received treatment with curative intent**



**surgery or radical radiotherapy



67% in 2021 68% in 2020 **74%** in 2019



of patients with NSCLC (stage IIIA, PS 0-2) received treatment with curative intent***



N/A

61% in 2021

48% in 2020

56% in 2019

***surgery, radical radiotherapy or multimodal combination with chemotherapy

Systemic anti-cancer therapy



of patients with NSCLC (stage IIIB - IV, PS 0-1) received systemic anticancer therapy





57% in 2021 **53%** in 2020 **55%** in 2019

Survival outcomes

2,211 patients were diagnosed between 1 January and 31 December 2022. For these patients:

Median survival

262 davs

222 days in 2021 **224** days in 2020

235 days in 2019

One year survival



39% in 2021 40% in 2020

***information on smoking status unavailable

42% in 2019

Data quality

Completeness of key routine data items***

90%

Audit standard

Stage

99%

Performance status

90%

Audit standard

Morphology 100%

75 % Audit standard

Basis of diagnosis



CNS at diagnosis





98% in 2021

97% in 2021

98%

100% in 2021

100% in 2021

98% in 2021